Doximity, Inc. (DOCS) Stock Analysis and Metrics

Sector: Healthcare Industry: Health Information Services CIK: 0001516513

Market Cap 4.23 Bn

P/E 17.98

P/S 6.62

Div. Yield 0.00

ROIC (Qtr) 0.20

Revenue Growth (1y) (Qtr) 9.76

Add ratio to table...

About

Doximity, Inc. (DOCS) operates as a leading digital platform for medical professionals in the United States, boasting over two million registered members as of March 31, 2024. The company's mission is to enhance physician productivity and improve patient care through its physician cloud, which provides medical professionals with digital tools tailored for their specific needs. Doximity's primary business activities revolve around its Marketing, Hiring, and Productivity Solutions, which serve pharmaceutical manufacturers, health systems, and medical...

Doximity, Inc. (DOCS) operates as a leading digital platform for medical professionals in the United States, boasting over two million registered members as of March 31, 2024. The company's mission is to enhance physician productivity and improve patient care through its physician cloud, which provides medical professionals with digital tools tailored for their specific needs.

Doximity's primary business activities revolve around its Marketing, Hiring, and Productivity Solutions, which serve pharmaceutical manufacturers, health systems, and medical recruiting firms. These solutions are designed to facilitate connections between healthcare professionals, enabling them to collaborate and communicate effectively, while also providing valuable resources and tools to streamline clinical workflows.

The company's revenue generation is primarily driven by its Marketing Solutions, which enable pharmaceutical manufacturers and health systems to reach the right medical professionals with targeted content, services, and peer connections. Doximity's Hiring Solutions offer digital recruiting capabilities to health systems and medical recruiting firms, allowing them to identify, connect with, and hire from Doximity's network of medical professionals. Additionally, the company's Productivity Solutions include telehealth, on-call scheduling, and AI-supported medical correspondence tools, all designed to help clinicians optimize their clinical workflows and easily connect with patients and colleagues.

Doximity's competitive advantages within the industry include its deep understanding of physician workflows, its strategic relationships with customers, and its seamless integration into these workflows. As a result, the company has established itself as a trusted partner for top pharmaceutical manufacturers, hospitals, and health systems. Despite competition from large technology companies and emerging startups, Doximity's focus on the unique needs of medical professionals sets it apart in the market.

Doximity's product and service offerings include Doximity GPT, a HIPAA-compliant generative AI writing assistant; Dialer, a telehealth product; AMiON, an on-call scheduling tool; and Residency Navigator, a tool for medical students to discover and compare training programs. These tools are designed to facilitate communication, collaboration, and productivity among healthcare professionals.

Investment thesis

Bull case

Doximity’s member base surpassed 3 million, with over 85 % of U.S. physicians and two‑thirds of NPs and PAs actively registered. This penetration gives the platform a network effect that is difficult for new entrants to replicate, especially given the trust that clinicians place in a peer‑verified ecosystem. The company’s record highs in quarterly, monthly, weekly, and daily active users—particularly for news feed, workflow, and AI products—show that physicians are not only joining but also deeply engaging across multiple verticals. This high engagement rate translates into recurring subscription revenue and creates a stable foundation for future upsell opportunities.
Revenue grew 10 % year‑over‑year to $185 million, exceeding the high end of guidance and marking a 2 % beat. The 60 % adjusted EBITDA margin underscores strong operating leverage and efficient cost management, especially when compared to the 61 % margin reported a year earlier. Even with the noted gross margin decline to 91 % due to AI infrastructure investments, the company has maintained a healthy free‑cash‑flow generation of $58.5 million in the quarter, which can fund strategic initiatives without external financing. This blend of revenue growth, margin strength, and cash flow resilience positions Doximity to accelerate investment in AI while preserving shareholder value.
Net revenue retention at 112 %—and 117 % for the top 20 customers—demonstrates robust expansion within the existing customer base. The fact that 84 % of total revenue is derived from 126 customers generating at least $500,000 each shows a concentration in large accounts, but it also indicates that the platform is delivering compelling value to enterprise‑level users. A high retention rate suggests that customers are willing to pay for incremental features and that churn risk is low, which is especially important in a market where alternative solutions could erode market share. Retention also supports the company’s ability to forecast revenue with greater precision and to justify premium pricing for advanced modules.
The acquisition of Pathway.ai and its seamless integration have accelerated AI adoption, with over 300,000 unique prescribers using Docs GPT in Q3. The product’s performance—outperforming competitors in a controlled trial—serves as a credible proof point that can drive additional adoption across health systems. By embedding AI into core workflows (e.g., telehealth visits, fax summarization), Doximity ensures that physicians interact with AI organically, increasing usage frequency and data capture for model refinement. This high adoption volume also signals that the forthcoming commercial AI products will likely hit the market with a pre‑existing, highly engaged user base, reducing time‑to‑revenue for future monetization.
Doximity Dialer has held the top spot among health‑system CIOs for five consecutive years, outperforming major competitors such as Microsoft Teams and Zoom. This dominance in a critical telehealth segment creates a strong moat, as CIOs increasingly prefer a single, integrated platform that can handle scheduling, video, fax, and AI. The platform’s unique integration with telephony providers ensures high call‑through rates and low spam flags, which enhances the user experience and cements institutional trust. Moreover, the continued leadership in this space signals that the company can leverage its position to cross‑sell additional modules and expand into new revenue streams.

Doximity’s member base surpassed 3 million, with over 85 % of U.S. physicians and two‑thirds of NPs and PAs actively registered. This penetration gives the platform a network effect that is difficult for new entrants to replicate, especially given the trust that clinicians place in a peer‑verified ecosystem. The company’s record highs in quarterly, monthly, weekly, and daily active users—particularly for news feed, workflow, and AI products—show that physicians are not only joining but also deeply engaging across multiple verticals. This high engagement rate translates into recurring subscription revenue and creates a stable foundation for future upsell opportunities.
Revenue grew 10 % year‑over‑year to $185 million, exceeding the high end of guidance and marking a 2 % beat. The 60 % adjusted EBITDA margin underscores strong operating leverage and efficient cost management, especially when compared to the 61 % margin reported a year earlier. Even with the noted gross margin decline to 91 % due to AI infrastructure investments, the company has maintained a healthy free‑cash‑flow generation of $58.5 million in the quarter, which can fund strategic initiatives without external financing. This blend of revenue growth, margin strength, and cash flow resilience positions Doximity to accelerate investment in AI while preserving shareholder value.
Net revenue retention at 112 %—and 117 % for the top 20 customers—demonstrates robust expansion within the existing customer base. The fact that 84 % of total revenue is derived from 126 customers generating at least $500,000 each shows a concentration in large accounts, but it also indicates that the platform is delivering compelling value to enterprise‑level users. A high retention rate suggests that customers are willing to pay for incremental features and that churn risk is low, which is especially important in a market where alternative solutions could erode market share. Retention also supports the company’s ability to forecast revenue with greater precision and to justify premium pricing for advanced modules.
The acquisition of Pathway.ai and its seamless integration have accelerated AI adoption, with over 300,000 unique prescribers using Docs GPT in Q3. The product’s performance—outperforming competitors in a controlled trial—serves as a credible proof point that can drive additional adoption across health systems. By embedding AI into core workflows (e.g., telehealth visits, fax summarization), Doximity ensures that physicians interact with AI organically, increasing usage frequency and data capture for model refinement. This high adoption volume also signals that the forthcoming commercial AI products will likely hit the market with a pre‑existing, highly engaged user base, reducing time‑to‑revenue for future monetization.
Doximity Dialer has held the top spot among health‑system CIOs for five consecutive years, outperforming major competitors such as Microsoft Teams and Zoom. This dominance in a critical telehealth segment creates a strong moat, as CIOs increasingly prefer a single, integrated platform that can handle scheduling, video, fax, and AI. The platform’s unique integration with telephony providers ensures high call‑through rates and low spam flags, which enhances the user experience and cements institutional trust. Moreover, the continued leadership in this space signals that the company can leverage its position to cross‑sell additional modules and expand into new revenue streams.

Bear case

The company’s revenue concentration—84 % from 126 customers generating at least $500,000 each—creates a significant risk of churn or reduced spend from a few large accounts. Any contractual renegotiation or loss of a top 20 customer could materially erode revenue and margin, given the current retention focus on high‑ticket clients. This concentration is especially vulnerable in a market experiencing policy uncertainty, where budgetary constraints may prompt customers to seek cheaper alternatives or to delay platform expansion. Diversifying the customer base is critical to mitigate this risk but may require additional marketing spend that could compress margins.
Policy uncertainty surrounding MFN agreements and other pharma‑industry budgetary mechanisms has already delayed bookings and pushed revenue into Q4. The company’s guidance maintains a flat full‑year outlook despite Q3 outperformance, reflecting the potential for sustained headwinds from these policy delays. If similar or new regulatory changes arise, the company could face further booking deferrals or reduced demand for advertising and AI modules. This uncertainty makes it difficult for management to project revenue growth accurately and could lead to earnings volatility that may alarm investors.
AI infrastructure investments have already pulled the non‑GAAP gross margin from 93 % to 91 %, indicating a cost escalation that may continue as AI adoption scales. While the company plans to monetize AI later in the year, the current lack of revenue from AI products exacerbates the margin pressure, especially if the rollout is delayed or if adoption is slower than anticipated. Additional AI spending without immediate revenue can erode cash flow and limit the firm’s capacity to invest in other growth levers, such as paid search or new product development.
Management’s emphasis on “AI safety” and the reference to a 22 % clinical harm rate from recent studies highlight an industry‑wide risk that could slow AI adoption. Even with a peer‑review system, the potential for misdiagnosis or erroneous recommendations poses a significant liability risk that could prompt regulatory scrutiny. Hospitals may impose stricter controls or opt for alternative AI solutions with lower perceived risk, which could limit Doximity’s ability to capture AI market share. The company’s current strategy relies heavily on trust, but the pace of regulatory development could outstrip its capacity to adapt quickly.
The CFO’s medical leave and the interim oversight by the audit committee chair introduce an element of uncertainty in financial governance and reporting. While the company has not disclosed any material financial irregularities, the absence of a dedicated CFO may affect the timeliness and depth of financial analysis, potentially impacting investor confidence. A prolonged CFO absence could also delay critical decisions on capital allocation, such as the timing of AI product launches or share‑repurchase programs, which could influence market perception of the company’s strategic direction.

The company’s revenue concentration—84 % from 126 customers generating at least $500,000 each—creates a significant risk of churn or reduced spend from a few large accounts. Any contractual renegotiation or loss of a top 20 customer could materially erode revenue and margin, given the current retention focus on high‑ticket clients. This concentration is especially vulnerable in a market experiencing policy uncertainty, where budgetary constraints may prompt customers to seek cheaper alternatives or to delay platform expansion. Diversifying the customer base is critical to mitigate this risk but may require additional marketing spend that could compress margins.
Policy uncertainty surrounding MFN agreements and other pharma‑industry budgetary mechanisms has already delayed bookings and pushed revenue into Q4. The company’s guidance maintains a flat full‑year outlook despite Q3 outperformance, reflecting the potential for sustained headwinds from these policy delays. If similar or new regulatory changes arise, the company could face further booking deferrals or reduced demand for advertising and AI modules. This uncertainty makes it difficult for management to project revenue growth accurately and could lead to earnings volatility that may alarm investors.
AI infrastructure investments have already pulled the non‑GAAP gross margin from 93 % to 91 %, indicating a cost escalation that may continue as AI adoption scales. While the company plans to monetize AI later in the year, the current lack of revenue from AI products exacerbates the margin pressure, especially if the rollout is delayed or if adoption is slower than anticipated. Additional AI spending without immediate revenue can erode cash flow and limit the firm’s capacity to invest in other growth levers, such as paid search or new product development.
Management’s emphasis on “AI safety” and the reference to a 22 % clinical harm rate from recent studies highlight an industry‑wide risk that could slow AI adoption. Even with a peer‑review system, the potential for misdiagnosis or erroneous recommendations poses a significant liability risk that could prompt regulatory scrutiny. Hospitals may impose stricter controls or opt for alternative AI solutions with lower perceived risk, which could limit Doximity’s ability to capture AI market share. The company’s current strategy relies heavily on trust, but the pace of regulatory development could outstrip its capacity to adapt quickly.
The CFO’s medical leave and the interim oversight by the audit committee chair introduce an element of uncertainty in financial governance and reporting. While the company has not disclosed any material financial irregularities, the absence of a dedicated CFO may affect the timeliness and depth of financial analysis, potentially impacting investor confidence. A prolonged CFO absence could also delay critical decisions on capital allocation, such as the timing of AI product launches or share‑repurchase programs, which could influence market perception of the company’s strategic direction.

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	32.14 Bn	15.36	1.56	10.00 Bn
2	VEEV	Veeva Systems Inc	28.37 Bn	31.15	8.88	-
3	BTSG	BrightSpring Health Services, Inc.	8.24 Bn	45.14	0.64	2.51 Bn
4	HQY	Healthequity, Inc.	7.17 Bn	33.88	5.46	0.96 Bn
5	WAY	Waystar Holding Corp.	4.57 Bn	37.24	4.15	1.47 Bn
6	DOCS	Doximity, Inc.	4.23 Bn	17.98	6.62	-
7	TXG	10x Genomics, Inc.	2.85 Bn	-63.74	4.43	-
8	PRVA	Privia Health Group, Inc.	2.59 Bn	110.37	1.22	-

Research Tools

Doximity, Inc. (NYSE: DOCS)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Doximity, Inc. (NYSE: DOCS)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password